🟢 Pacific Biosciences is trading 7% up today after EpiSign–Geneyx rare-disease partnership

Pacific Biosciences is trading at $3.07, up +7.04%, as an EpiSign–Geneyx partnership uses PacBio HiFi data for rare-disease interpretation.

• The agreement integrates genomic and epigenomic analysis and extends automated analysis across more than 300 disorders.
• Reported alongside a sharp October 5 move, the partnership had no separate October 6 company announcement. Broader indices were positive but below the 0.5% threshold, making company news the clearest reported explanation.